

Subject Index

- acid phosphatase 51
- actinomycin D in bladder carcinoma 44
 - in renal cell carcinoma 132
 - in testicular cancer 92-93
- adriamycin (*see also* doxorubicin) 66
 - in renal cell carcinoma 132
 - in testicular cancer 93
- alanine mustard in prostatic carcinoma 60
- alpha-fetoprotein (AFP) 79
- Bacillus Calmette Guerin (*see* BCG)
- Baker's antifol in renal cell carcinoma 132
- BCG bladder tumors and intravesical injection 24
 - intravesical immunotherapy 23-24
 - - -, antibody response 24
 - - -, dosage and administration 24
 - - -, prophylactic 24
 - - -, response rates 24
 - - -, side effects 24
- BCNU in prostatic carcinoma 60
- bladder carcinoma histology 3
 - - incidence of invasion 4-9
 - - - and mortality 3
 - - - response criteria 55
 - - in situ BCG intravesical immunotherapy 24
 - - - doxorubicin intravesical chemotherapy 20
 - - - natural history 7-8
 - - - urethral involvement, incidence 8
 - - staging 3
 - endoscopic evaluation 9
 - tumors natural history 4-9
 - - recurrence rate 4-9
 - - - - prophylaxis BCG 24
 - - - - prophylactic doxorubicin 20-22
 - - - - mitomycin 18
 - - - - - prophylactic teniposide 23
- - - - - prophylactic thiotepa 13-14
- - superficial 3-36
 - - - implantation 8-9
 - - - thiotepa prophylaxis 14
 - - - intravesical chemotherapy 9-36
 - - - - BCG 23-25
 - - - - doxorubicin 19-22
 - - - - ethoglucid 16-17
 - - - - mitomycin 17-19
 - - - - teniposide 22-23
 - - - - thiotepa 13-16
 - urinary, carcinoma 37
- bleomycin 41, 42
 - in advanced bladder carcinoma 41, 42
 - in penile carcinoma 144-145
 - in renal cell carcinoma 132
 - in superficial bladder tumors 10
 - in testicular cancer 93
- bone scans in prostatic carcinoma 50
- carcinoma bladder 37
 - - superficial 3-36, 38, 40
 - transitional cell 37
- cardiovascular safety 58
- carmustine (*see* BCNU)
- chemotherapy bladder carcinoma 37
 - intravesical absorption of drugs 11-13
 - - agents 10
 - - effect on urothelium 12
 - - patient care 27
 - - pharmacologic considerations 13
- chlorambucil 38
- Cis-diamminedichloroplatinum II (cisplatin) 40-41, 42-45
 - - combinations 42-44
- cisplatin in advanced bladder carcinoma 42, 43
 - nephrotoxicity 41
 - in prostatic carcinoma 61, 65, 67
 - in superficial bladder tumors 10

- in testicular cancer 93
- cisplatinum in penile carcinoma 145
- CT scans (computerized tomography) in bladder tumors 55
 - - - in renal cell carcinoma 123, 124
 - - - in testicular tumors 54, 76-78
- cyclophosphamide 38, 42
 - combinations 43, 44
 - in prostatic carcinoma 60, 61, 63, 64
 - - - combination chemotherapy 61
 - in testicular cancer 88
- cytosine arabinoside in renal cell carcinoma 133

- dacarbazine (DTIC) in prostatic carcinoma 61, 64
- dianhydrogalactitol in renal cell carcinoma 133
- diethylstilbestrol (DES) in prostatic carcinoma 58
- doxorubicin (adriamycin) in bladder carcinoma 39-40, 42-45
 - - - - combination 43-44
 - - intravesical chemotherapy 10-13, 19-22
 - - - - availability, cost 22
 - - - - carcinoma in situ 20
 - - - - in combination with radiotherapy 28
 - - - - dosage and administration 21
 - - - - prophylactic 20-21
 - - - - recurrence rates 20-21
 - - - - response rates 19-20, 27
 - - - - systemic absorption 11-13
 - - - - toxicity 21-22
 - - in prostatic carcinoma 61, 64
 - - - - response rates 62

- epodyl (*see* ethoglucid)
- estramustine in prostatic carcinoma 61, 64, 66
- ethoglucid (epodyl) intravesical chemotherapy 16-17
 - - - - availability 17
 - - - - dosage and administration 16-17
 - - - - response rate 16-17, 27
 - - - - toxicity 17

- FANFT tumor model 41
- 5-fluorouracil (5-FU) 38-39, 42
 - - combination 43-44
 - - in prostatic carcinoma 60, 61, 64
 - - radiation 38
 - - in renal cell carcinoma 133
 - - surgery 38
 - - in testicular cancer 89
- FUDR in prostatic carcinoma 60
 - in renal cell carcinoma 133

- gynecomastia in prostatic carcinoma 58

- Helmsteins distension, in superficial bladder tumors 18
- hexamethylmelamine 41, 42
- hydrostatic pressure in superficial bladder tumors 28
- hydroxyurea in prostatic carcinoma 61, 65
 - in renal cell carcinoma 133
- hyperthermia in superficial bladder tumors 28

- immunotherapy in superficial bladder tumors 23-24
- interferon 41

- lomustine (CCNU) in prostatic carcinoma 61, 65
- lymphangiograms in testicular cancer 78

- m-AMSA in prostatic carcinoma 61
 - in renal cell carcinoma 133
- MeCCNU in prostatic carcinoma 61, 65
- melfhalan 38
 - in bladder carcinoma 38
 - in prostatic carcinoma 61, 65
- 6-mercaptopurine in renal cell carcinoma 133
- methidichlorophen in renal cell carcinoma 132
- methotrexate 39, 42, 45
 - in bladder carcinoma 39, 42, 45
 - combination 44
 - in penile carcinoma 145
 - in prostatic carcinoma 60, 65
 - in renal cell carcinoma 132
 - in superficial bladder tumors 10-11, 26
 - in testicular cancer 88-89
- methyl-Gag in renal cell carcinoma 133
- metoclopramide 41
- mithramycin in prostatic carcinoma 60
 - in renal cell carcinoma 132
 - in testicular cancer 90-91
- mitomycin C (MM) 40, 42
 - - intravesical chemotherapy 10-13, 17-19, 40

- - - - cost 19
- - - - dosage and administration 19
- - - - response rates 17-18, 27
- - - - - , thiotepa failures 18
- - - - systemic absorption 12-13
- - - - toxicity 18-19
- mitotane in renal cell carcinoma 133
- nafoxidine in renal cell carcinoma 128
- National Prostate Cancer Project (NPCP) 60
- neocarcinostatin 41, 42
- nitrogen mustard 38
- nitrosourea 38, 41
- orchiectomy 58
- PALA 42
- penile carcinoma, bleomycin 144-145
 - -, chemotherapy 143-146
 - -, cisplatin 145
 - -, methotrexate 145
 - -, radiation therapy 144-145
- phenylalanine mustard in testicular cancer' 88
- piperezinedione in renal cell carcinoma 133
- prednimustine in prostatic carcinoma 61, 65
- procarbazine in prostatic carcinoma 61, 64
- prostatic carcinoma bone scans 50-51
 - -, chemotherapeutic agents 60-67
 - -, response rates 61
 - -, chemotherapy 58-69
 - -, hormonal treatment 58
 - -, natural history 52
 - -, response criteria 50-54
 - -, stabilization criteria 54
 - -, time to response 59
- pyridoxine in superficial bladder tumors 25
- radiotherapy in penile carcinoma 144-145
 - in superficial bladder tumors 26-28
 - - - in combination with doxorubicin 28
 - - - irridium-192 28
 - - - radium needle implantation 26-27
- rehabilitation in testicular cancer 117
- renal androgen therapy 127
 - cell carcinoma 123-142
 - chemotherapy 130-135
 - combination 134-135
 - single agent 130-133
- - - - alkaloids 130
- - - - alkylators 131
- - - - antibiotics 132
- - - - folate antagonists 132
- - - - purine antagonists 133
- - - - pyrimidine antagonists 133
- hormonal treatment 126
 - - and chemotherapy 129
- natural history 123
- nephrectomy to control metastatic disease 125
- progestational agents 127
- radiotherapy 124
- response criteria 55
- staging 123, 124
- surgery 124
 - - removal of single and multiple metastases 125
- retinoids (13-cis-retinoic acid) in superficial bladder tumors 25-26
- seminomas 85
- streptozocin in prostatic carcinoma 61, 64
- tamoxifen in renal cell carcinoma 128
- teniposide (VM-26) intravesical chemotherapy 22-23
 - - prophylaxis, comparison with doxorubicin, mitomycin C 23
- testes incidence of tumors 70
 - risk factors 70-71
 - scalene lymph node biopsy 76
 - tumors, chemotherapy 87-117
 - -, adjuvant 113
 - -, combination 94
 - -, single agent 88
 - -, histopathologic classifications 71
 - -, - choriocarcinoma 73
 - -, - embryonal 73
 - -, - seminoma 72
 - -, - yolk sac 73
 - -, histopathology 71-73
 - -, natural history 70-71
- testicular carcinoma, complete response 54
 - -, partial response 54
 - -, radiotherapy 82-84
 - -, response criteria 54
 - -, surgery 54-55, 81-82
- thiotepa intravesical chemotherapy 10-16
 - - availability and cost 15
 - - dosage and administration 14-15
 - - prophylaxis 13-14, 16
 - - after surgery 14

- - - response rates 13-15, 27
- - - systemic absorption 11-13
- - - toxicity 15
- thymosin 41
- triazinate in renal cell carcinoma 132
- triple therapy in testicular cancer 95-96
- tumor markers in testicular cancer 79

- 290 ultrasound in testicular cancer 78

- VAB regimens in testicular cancer 102
- VACURG (Veterans Administration Co-operative Research Group) 52, 58
- vinblastine 41, 42
 - in testicular cancer 89
- vincristine 41, 42
 - combination 44
 - in prostatic carcinoma 60, 61, 65
 - in testicular cancer 89
- vindesine in renal cell carcinoma 130
- vitamin A (*see* retinoic acid)
- VM-26 (*see* also teniposide) 41, 42
 - combinations 44
 - in superficial bladder tumors 22, 23
- VP-16-213 (etoposide) 41, 42
 - in testicular cancer 110

- Yoshi 864 42

Recent Results in Cancer Research

Sponsored by the Swiss League against Cancer. Editor in Chief: P. Rentchnick, Genève

For information about Vols. 1-9, please contact your bookseller of Springer-Verlag

- 10 NELSON, R. S.: Radioactive Phosphorus in the Diagnosis of Gastrointestinal Cancer.
- 11 FREEMAN, R. G. and J. M. KNOX: Treatment of Skin Cancer.
- 12 LYNCH, H. T.: Hereditary Factors in Carcinoma.
- 13 Tumours in Children, 2nd Edition. Edited by H. B. MARSDEN and J. K. STEWARD.
- 14 ODARTCHENKO, N.: Production Cellulaire Erythropoïétique.
- 15 SOKOLOFF, B.: Carcinoid and Serotonin.
- 16 JACOBS, M. L.: Malignant Lymphomas and Their Management.
- 17 Normal and Malignant Cell Growth. Edited by R. J. M. FRY, M. L. GRIEM, and W. H. KIRSTEN (Symposium).
- 18 ANGLÉSIO, E.: The Treatment of Hodgkin's Disease.
- 19 BANNASCH, P.: The Cytoplasm of Hepatocytes during Carcinogenesis. Electron- and Lightmicroscopical Investigations of the Nitrosomorpholineintoxicated Rat Liver.
- 20 Rubidomycin. A new Agent against Cancer. Edited by J. BERNARD, R. PAUL, M. BOIRON, C. JACQUILLAT, and R. MARAL.
- 21 Scientific Basis of Cancer Chemotherapy. Edited by G. MATHÉ (Symposium).
- 22 KOLDOVSKÝ, P.: Tumor Specific Transplantation Antigen.
- 23 FUCHS, W. A., J. W. DAVIDSON, and H. W. FISCHER: Lymphography in Cancer. With contributions by G. JANTET and H. RÖSLER.
- 24 HAYWARD, J.: Hormones und Human Breast Cancer. An Account of 15 Years Study.
- 25 ROY-BURMAN, P.: Analogues of Nucleic Acid Components. Mechanisms of Action.
- 26 Tumors of the Liver. Edited by G. T. PACK and A. H. ISLAMI.
- 27 SZYMENDERA, J.: Bone Mineral Metabolism in Cancer.
- 28 MEEK, E. S.: Antitumour and Antiviral Substances of Natural Origin.
- 29 Aseptic Environments and Cancer Treatment. Edited by G. MATHÉ (Symposium).
- 30 Advances in the Treatment of Acute (Blastic) Leukemias. Edited by G. MATHÉ (Symposium).
- 31 DENOIX, P.: Treatment of Malignant Breast Tumors. Indications and Results.
- 32 NELSON, R. S.: Endoscopy in Gastric Cancer.
- 33 Experimental and Clinical Effects of L-Asparaginase. Edited by E. GRUNDMANN and H. F. OETTGEN (Symposium).
- 34 Chemistry and Biological Actions of 4-Nitroquinolin 1-Oxide. Edited by H. ENDO, T. ONO, and T. SUGIMURA.
- 35 PENN, I.: Malignant Tumors in Organ Transplant Recipients.
- 36 Current Concepts in the Management of Lymphoma and Leukemia. Edited by J. E. ULTMANN, M. L. GRIEM, W. H. KIRSTEN, and R. W. WISSLER (Symposium).
- 37 CHIAPPA, S., R. MUSUMECI, and C. USLENGHI: Endolymphatic Radiotherapy in Malignant Lymphomas. With contributions by G. BONADONNA, B. DAMASCELLI, G. FAVA, F. PIZZETTI, U. VERONESI.
- 38 KOLLER, P. C.: The Role of Chromosomes in Cancer Biology.
- 39 Current Problems in the Epidemiology of Cancer and Lymphomas. Edited by E. GRUNDMANN and H. TULINIUS (Symposium).
- 40 LANGLEY, F. A. and A. C. CROMPTON: Epithelial Abnormalities of the Cervix Uteri.
- 41 Tumours in a Tropical Country. A Survey of Uganda (1964-1968). Edited by A. C. TEMPLETON.
- 42 Breast Cancer: A Challenging Problem. Edited by M. L. GRIEM, E. V. JENSEN, J. E. ULTMANN, and R. W. WISSLER (Symposium).
- 43 Nomenclature, Methodology and Results of Clinical Trials in Acute Leukemias. Edited by G. MATHÉ, P. POUILLART, L. SCHWARZENBERG (Symposium).
- 44 Special Topics in Carcinogenesis. Edited by E. GRUNDMANN (Symposium).
- 45 KOLDOVSKÝ, P.: Carcinoembryonic Antigens. Diagnosis and Therapy of Malignant Lymphoma. Edited by K. MUSSHOF (Symposium).
- 46 Investigation and Stimulation of Immunity in Cancer Patients. Edited by G. MATHÉ and R. WEINER (Symposium).
- 47 Platinum Coordination Complexes in Cancer Chemotherapy. Edited by T. A. CONNORS and J. J. ROBERTS (Symposium).
- 48 Complications of Cancer Chemotherapy. Edited by G. MATHÉ and R. K. OLDHAM (Symposium).
- 49 Cancer Registry, Edited by E. GRUNDMANN and E. PEDERSEN (Symposium).
- 50 Gliomas. Current Concepts in Biology, Diagnosis and Therapy. Edited by J. HEKMATPAHAH (Symposium).

- 52 The Ambivalence of Cytostatic Therapy. Edited by E. GRUNDMANN and R. GROSS (Symposium).
- 53 A. CLARYSSE, Y. KENIS, and G. MATHÉ: Cancer Chemotherapy.
- 54 Malignant Bone Tumors. Edited by E. GRUNDMANN.
- 55 MATHÉ, G.: Cancer Active Immunotherapy, Immunoprophylaxis, and Immunorestitution.
- 56 Lymphocytes, Macrophages, and Cancer. Edited by G. MATHÉ, I. FLORENTIN, and M.-C. SIMMLER (Symposium).
- 57 Breast Cancer: A Multidisciplinary Approach. Edited by G. St. ARNEAULT, P. BAND, and L. ISRAËL (Symposium).
- 58 B. S. SCHOENBERG: Multiple Primary Malignant Neoplasms.
- 59 Selective Heat Sensitivity of Cancer Cells. Edited by A. ROSSI-FANELLI, R. CAVALIERE, B. MONDOVI, and G. MORICCA.
- 60 Tumors of the Male Genital System. Edited by E. GRUNDMANN and W. VAHLENSIECK (Symposium).
- 61 D. METCALF: Hemopoietic Colonies.
- 62 Tactics and Strategy in Cancer Treatment. Edited by G. MATHÉ (Symposium).
- 63 Antitumor Antibiotics. Edited by S. K. CARTER, H. UMEZAWA, J. DOUROS, and Y. SAKURAI (Symposium).
- 64 Lymphoid Neoplasias I: Classification, Categorization, Natural History.
- 65 Lymphoid Neoplasias II: Clinical and Therapeutic Aspects.
Lymphoid Neoplasias I & II. Proceedings of the 1977 CNRS-EORTC International Colloquium. Editors: G. MATHÉ, M. SELIGMANN, M. TUBIANA. Divided into two volumes.
- 66 Carcinogenic Hormones. Edited by C. H. LINGEMAN.
- 67/68 Adjuvant Therapies and Markers of Post-Surgical Minimal Residual Disease I & II. Proceedings of the 1978 Annual Plenary Meeting of the EORTC. Editors: G. BONADONNA, G. MATHÉ, S. E. SALMON. Divided into two volumes.
- 67 Markers and General Problems of Cancer Adjuvant Therapies.
- 68 Adjuvant Therapies of the Various Primary Tumors.
- 69 Strategies in Clinical Hematology. Edited by R. GROSS and K.-P. HELLRIEGEL.
- 70 New Anticancer Drugs. Edited by S. K. CARTER
- 71 Endocrine Treatment of Breast Cancer. Edited by B. HENNINGSEN, F. LINDER, C. STREICHELE.
- 72 CAWLEY, J. C., BURNS, G. F., HAYHOE, F. G. J.: Hairy-Cell Leukaemia.
- 73 Thyroid Cancer. Edited by W. DUNCAN.
- 74 Cancer Chemo- and Immunopharmacology. 1. Chemopharmacology. Edited by G. MATHÉ and F. M. MUGGIA.
- 75 Cancer Chemo- and Immunopharmacology. 2. Immunopharmacology, Relations and General Problems. Edited by G. MATHÉ and F. M. MUGGIA.
- 76 New Drugs in Cancer Chemotherapy. Edited by S. K. CARTER, Y. SAKURAI, H. UMEZAWA
- 77 K. STANLEY, J. STJERNSWÄRD, M. ISLEY: The Conduct of a Cooperative Clinical Trial.
- 78 Prostate Cancer. Edited by W. DUNCAN.
- 79 Chemotherapy and Radiotherapy of Gastrointestinal Tumors. Edited by H. O. KLEIN.
- 80 Adjuvant Therapies of Cancer. Edited by G. MATHÉ, G. BONADONNA, S. SALMON.
- 81 H. P. LOHRMANN and W. SCHREML: Cytotoxic Drugs and the Granulopoietic System.
- 82 Early Detection and Localization of Lung Tumors in High Risk Groups. Edited by P. R. BAND.
- 83 Colorectal Cancer. Edited by W. DUNCAN.
- 84 Modified Nucleosides and Cancer. Edited by G. NASS.
- 85 Urologic Cancer: Chemotherapeutic Principles and Management. Edited by F. M. TORTI.